Exenatide versus Insulin Glargine in Patients with Suboptimally Controlled Type 2 Diabetes
Eli Lilly (United States) · Antwerp University Hospital
Indexed incrossrefpubmed
Abstract
Background
Physicians may use either insulin or exenatide injections for patients with type 2 diabetes mellitus who have poor glycemic control despite taking oral blood glucose-lowering drugs.
Objective
To compare effects of exenatide and insulin glargine on glycemic control in patients with type 2 diabetes mellitus that is suboptimally controlled with metformin and a sulfonylurea.
Citation impact
797
total citations
- FWCI
- 38.74
- Percentile
- 100%
- References
- 33
Citations per year
Authors
7- RJRobert J. HeineCorresponding
Eli Lilly (United States), Antwerp University Hospital
- LFLuc F. Van Gaal
Antwerp University Hospital, Eli Lilly (United States)
- DJDon Johns
Eli Lilly (United States), Antwerp University Hospital
- MJMichael J. Mihm
Antwerp University Hospital, Eli Lilly (United States)
- MWMario Widel
Eli Lilly (United States), Antwerp University Hospital
Topics & keywords
Topics
Keywords
- Exenatide
- Medicine
- Insulin glargine
- Internal medicine
- Glycemic
- Hypoglycemia
- Sulfonylurea
- Metformin
No related works found for this paper.